Imexpharm (IMP): Stable margin profile and low leverage, but limited upside and low model confidence
Intrinsic value VND 39,200 vs market price VND 36,700; implied upside 6.8% (model confidence: very_low).
Tổng quan doanh nghiệp
Công ty Cổ phần Dược phẩm Imexpharm (IMP) is a HOSE-listed pharmaceutical manufacturer and distributor operating in the Vietnamese 'Dược phẩm' sector. The company reported revenue of VND 2,441.1 bn in 2025 (up from VND 1,994.0 bn in 2023) and net profit of VND 349.1 bn in 2025. IMP's product mix is concentrated in domestic branded generics and OTC medicines, serving both retail pharmacy channels and institutional procurement.
Luận điểm đầu tư
IMP exhibits a healthy profitability profile for a domestic pharma player: a gross margin of 41.0% and an EBIT margin of 18.9% support a net profit margin of 14.3% in the latest ratios. Return on equity is 15.6% and ROA 13.2%, consistent with mid-single-digit to high-single-digit growth in revenue (Revenue YoY 15.98% in the latest period). Balance-sheet metrics show low leverage with Debt/Equity of 0.2064 and net debt of VND 23,586,003,736 in the DCF inputs, providing flexibility for capex or dividends.
Bình luận định giá
Blended intrinsic value combining a DCF (70% weight) and a P/E approach (30% weight) to produce a per-share fair value.
- Base FCF used: VND 184,299,450,718
- WACC: 10.0%; terminal growth: 4.0%; projection horizon: 10 years; terminal value portion: 61.34% of enterprise value
- PE inputs: fair P/E 20.54 with a P/E cap of 25 used in the PE leg
- Growth: blended firm-level growth of 14.96% driven by ROIC 18.3% and a reinvestment rate 85.37%
- Net debt used in valuation: VND 23,586,003,736; raw (pre-calibration) intrinsic: VND 36,909.6; calibrated intrinsic: VND 39,200
The blended intrinsic value of VND 39,200 implies only 6.8% upside versus the current price of VND 36,700. The model flags low liquidity and potential manipulation risk and reports very_low confidence, so the implied narrow upside is not sufficient to overcome execution and model uncertainty. Confidence in the intrinsic estimate is very_low, so position sizing should be conservative and contingent on confirmatory operational data.
Quan điểm tích cực và tiêu cực
- Healthy margins: gross margin 41.03% and EBIT margin 18.94% support resilient net margin of 14.30%, underpinning strong cash generation.
- Low leverage: Debt/Equity 0.2064 gives scope for reinvestment or shareholder returns without stressing the balance sheet.
- Historical revenue growth: 3-year CAGR visible (2023 VND 1,994.0 bn to 2025 VND 2,441.1 bn) with Revenue YoY at 15.98% supporting the model's high growth assumption (14.96%).
- Very_low model confidence: valuation confidence explicitly 'very_low' and sanity_flags include 'low_liquidity' and 'manipulation_risk', reducing conviction in the VND 39,200 target.
- Narrow upside: implied upside 6.8% is within a range that offers little margin of safety versus execution or sector risk.
- Concentrated ownership: LIAN SGP HOLDING PTE. LTD. holds 67.88% and Tổng Công ty Dược Việt Nam 22.04%, which may limit free float and liquidity (foreign_room = 8158503.094870007).
Bối cảnh ngành
Vietnamese pharmaceuticals are affected by VAS accounting conventions for inventory and slow-moving stock recognition, and regulation around drug pricing can compress margins for certain product lines. State-related shareholders (Tổng Công ty Dược Việt Nam holds 22.04%) and the presence of large foreign strategic investors reflect sector consolidation and SOE interaction. Peer valuation dispersion is wide: sector median upside is 12.1% while top peers show >36% upside in our universe, indicating idiosyncratic outcomes are common in this sector.
Yếu tố rủi ro
- Valuation model confidence: the valuation is tagged 'very_low' and model_inputs.sanity_flags include 'low_liquidity' and 'manipulation_risk', increasing execution risk on the price target.
- Large shareholder concentration: top holder LIAN SGP HOLDING PTE. LTD. owns 67.88%, and combined top two owners exceed 89%, which reduces free float and can amplify price moves on block trades.
- Regulatory and pricing risk: drug price controls or hospital procurement rules could compress margins or slow revenue growth for certain therapeutic categories.
- Liquidity risk: low average daily volume (avg_volume_2w 13,102) may widen spreads and hinder tactical portfolio adjustments.
- Foreign ownership and room: foreign_room 8158503.094870007 shares may limit non-resident inflows; market demand can be lumpy.
- Model sensitivity to growth and WACC: the DCF uses a high growth input (14.96%) and WACC 10.0%; small changes materially alter the intrinsic value given terminal value sensitivity (TV_pct 0.6134).
Yếu tố xúc tác
- Quarterly results that sustain >15% revenue growth and stable margins could validate the model's growth assumptions.
- A corporate action (dividend increase or buyback) would improve free-float dynamics and could re-rate the stock given current dividend yield 1.63%.
- Regulatory clarity on drug pricing or favorable procurement contract wins could be a positive operational catalyst.
Đánh giá pháp y tài chính
No Beneish M-Score is provided (mscore is null) and there are no explicit forensic red flags in the forensic.summary or red_flags arrays. However, the valuation model's sanity_flags include 'low_liquidity' and 'manipulation_risk', and earnings quality is moderate at 58.9/100. Given concentrated ownership and low liquidity, be alert to atypical trading patterns or one-off accounting items; no definitive accounting manipulation signals are present in the supplied forensic fields.
Lịch sử dự báo
Historical model performance over 12 years shows a hit_rate of 72.7% and an average realized upside of 142.4% for past calls. While the hit rate is solid, past average upside is heavily skewed by large winners; use the historical hit rate as supportive but not definitive evidence, especially given the current model's very_low confidence calibration.
Được viết bởi mô hình ngôn ngữ ngày 2026-08-10 dựa trên kết quả mô hình và báo cáo tài chính của chính trang này, và có thể trích dẫn số liệu tại thời điểm đó. Đây là phân tích mô tả, không phải khuyến nghị đầu tư — không đưa ra hay hàm ý bất kỳ khuyến nghị mua, bán hay nắm giữ nào.